What Is Tirzepatide? The Dual GIP/GLP-1 Research Peptide Explained
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist studied in metabolic, cardiovascular, and body composition research. Here is what the science shows.
Research overviews of individual compounds including BPC-157, Ipamorelin, MOTS-C, NAD+, CJC-1295, TB-500, and other research peptides.
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist studied in metabolic, cardiovascular, and body composition research. Here is what the science shows.
Tirzepatide and Semaglutide are both GLP-1-based research peptides, but their mechanisms differ significantly. This comparison breaks down what makes each compound unique in research models.
Semaglutide is a GLP-1 receptor agonist studied for its role in glucose metabolism, appetite regulation, and cardiovascular research. This guide breaks down its mechanism of action.
Research peptides are short chains of amino acids used in scientific studies to explore biological processes. This guide explains what they are, how they work, and why purity matters.
Comprehensive research overview of the Khavinson peptide bioregulator program — Epithalon, Thymalin, Vilon, Livagen, Pinealon, Vesugen, and their combined use in longevity and aging research protocols.
Research guide for Sermorelin (GRF 1-29), a synthetic GHRH analogue studied for pituitary GH stimulation, somatopause, and body composition research. For laboratory research use only.
Research guide for Humanin, a 21-amino acid mitochondria-derived peptide (MDP) studied for neuroprotection, cytoprotection, metabolic regulation, and longevity biology. For laboratory research use only.
Research overview of MK-677 (Ibutamoren), an orally active growth hormone secretagogue and ghrelin mimetic studied for GH release, lean mass, bone density, and metabolic research. For laboratory research use only.
Research profile of GHRP-2 (Growth Hormone Releasing Peptide-2), a synthetic hexapeptide GHSR-1a agonist studied for GH secretion, body composition, and IGF-1 elevation. For laboratory research use only.
Research overview of Orforglipron, Eli Lilly’s oral small-molecule GLP-1 receptor agonist studied for obesity and type 2 diabetes. Phase 3 data published in NEJM 2026. For laboratory research use only.